Drugs / YL-17231
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06096974 | Oct 2023 → Oct 2025 overdue | cancer | Shanghai YingLi Pharmaceutical Co. Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06078800 | Sep 2023 → Mar 2025 | neoplasm | Shanghai YingLi Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-07-07 | 280Bio, Inc. | Regulatory 280Bio receives IND approval from the FDA for YL-17231 280bio.com ↗
280Bio, Inc. a clinical stage biotechnology company focused on the development of precision oncology medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted the company’s Investigational New Drug (IND) application for the investigational drug YL-17231, a small molecule inhibitor of RAS signaling. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-07-07 | 280Bio, Inc. | 280Bio receives IND approval from the FDA for YL-17231 280bio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YL-17231 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06096974 ↗ |
| Action | Inhibit | “Pan-KRAS Inhibitor YL-17231” NCT06078800 ↗ |
| Route | Oral | “eligible patients will receive oral YL-17231 once or twice daily” NCT06078800 ↗ |
| Target | KRAS | “Pan-KRAS Inhibitor YL-17231” NCT06078800 ↗ |